Exact Mass: 348.21479220000003

Exact Mass Matches: 348.21479220000003

Found 81 metabolites which its exact mass value is equals to given mass value 348.21479220000003, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

NCIOpen2_008175

9-Fluoro-17beta-hydroxy-6alpha,17-dimethylandrost-4-ene-3,11-dione

C21H29FO3 (348.2100616)


   

21-Fluoro-11beta-hydroxyprogesterone

21-Fluoro-11-hydroxy-pregn-4-ene-3,20-dione, (11beta)-

C21H29FO3 (348.2100616)


   

MLS002638463

9alpha-Fluoro-11beta-hydroxy-4-pregnene-3,20-dione

C21H29FO3 (348.2100616)


   

DTXSID101006060

6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate

C21H29FO3 (348.2100616)


   

TTNPB

4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid

C24H28O2 (348.2089188)


D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D000970 - Antineoplastic Agents

   

Bexarotene

4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid

C24H28O2 (348.2089188)


Bexarotene is only found in individuals that have used or taken this drug. It is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposis sarcoma (Wikipedia). Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XF - Retinoids for cancer treatment C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D000970 - Antineoplastic Agents

   

Roxatidine acetate

({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}carbamoyl)methyl acetate

C19H28N2O4 (348.20489680000003)


Roxatidine acetate is only found in individuals that have used or taken this drug. It is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked. D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents

   

4-[2-(5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid

4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl]benzoic acid

C24H28O2 (348.2089188)


   

bixin aldehyde

4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedial

C24H28O2 (348.2089188)


Bixin aldehyde is practically insoluble (in water) and an extremely weak basic (essentially neutral) compound (based on its pKa). Bixin aldehyde can be found in a number of food items such as bamboo shoots, sago palm, welsh onion, and globe artichoke, which makes bixin aldehyde a potential biomarker for the consumption of these food products.

   
   

Longistyline D

3,5-Dihydroxy-2,6-diisopentenylstilbene

C24H28O2 (348.2089188)


   

3,5-dihydroxy-4,6-diprenylstilbene

3,5-dihydroxy-4,6-diprenylstilbene

C24H28O2 (348.2089188)


   
   
   

Amorphastilbol

3,5-Dihydroxy-4-geranylstilbene

C24H28O2 (348.2089188)


   

2(S)-7-Hydroxy-2-methyl-2-(4-methyl-3-pentenyl)-5-(2-phenylethyl)chromene

2(S)-7-Hydroxy-2-methyl-2-(4-methyl-3-pentenyl)-5-(2-phenylethyl)chromene

C24H28O2 (348.2089188)


   
   

3,5-dihydroxy-2,6-diprenylstilbene

3,5-dihydroxy-2,6-diprenylstilbene

C24H28O2 (348.2089188)


   
   
   
   

2,7,7,10-Tetramethyl-4-pentyl-7H-benzo[c]furo[2,3-f]chromene #

2,7,7,10-Tetramethyl-4-pentyl-7H-benzo[c]furo[2,3-f]chromene #

C24H28O2 (348.2089188)


   

2-(3,7-dimethylocta-2,6-dienyl)-5-(2-phenylethenyl)benzene-1,3-diol

2-(3,7-dimethylocta-2,6-dienyl)-5-(2-phenylethenyl)benzene-1,3-diol

C24H28O2 (348.2089188)


   

7-Hydroxy-2-methyl-2-(4-methyl-3-penten-1-yl)-5-(2-phenylethyl)-2H-1-benzopyran

7-Hydroxy-2-methyl-2-(4-methyl-3-penten-1-yl)-5-(2-phenylethyl)-2H-1-benzopyran

C24H28O2 (348.2089188)


   
   

Bexarotene

4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid

C24H28O2 (348.2089188)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XF - Retinoids for cancer treatment C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D000970 - Antineoplastic Agents CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6073; ORIGINAL_PRECURSOR_SCAN_NO 6071 CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6096; ORIGINAL_PRECURSOR_SCAN_NO 6094 CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6097; ORIGINAL_PRECURSOR_SCAN_NO 6096 CONFIDENCE standard compound; INTERNAL_ID 501; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6100; ORIGINAL_PRECURSOR_SCAN_NO 6095 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3295

   

Roxane

({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}carbamoyl)methyl acetate

C19H28N2O4 (348.20489680000003)


D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents

   

Bixindial/ Bixin aldehyde

Bixindial/ Bixin aldehyde

C24H28O2 (348.2089188)


   

6,9,12,15,18-Tetracosapentaynoic acid

6,9,12,15,18-Tetracosapentaynoic acid

C24H28O2 (348.2089188)


   

FA 24:10

6,9,12,15,18-Tetracosapentaynoic acid

C24H28O2 (348.2089188)


   

bhas#18

3R-hydroxy-10R-(3R,5R-dihydroxy-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-undecanoic acid

C17H32O7 (348.21479220000003)


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#18 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans as well as the sour paste nematode, Panagrellus redivivus.

   

bhos#18

3R-hydroxy-11-(3R,5R-dihydroxy-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-undecanoic acid

C17H32O7 (348.21479220000003)


An omega-hydroxy fatty acid ascaroside that is oscr#18 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.

   

Bixindial

6,6-Diapocarotene-6,6-dial

C24H28O2 (348.2089188)


   

BENZYL 4-((TERT-BUTOXYCARBONYL)(METHYL)AMINO)PIPERIDINE-1-CARBOXYLATE

BENZYL 4-((TERT-BUTOXYCARBONYL)(METHYL)AMINO)PIPERIDINE-1-CARBOXYLATE

C19H28N2O4 (348.20489680000003)


   

1-Butyl-3-methylimidazolium octyl sulfate

1-Butyl-3-methylimidazolium octyl sulfate

C16H32N2O4S (348.2082672)


   

Leiopyrrole

Leiopyrrole

C23H28N2O (348.2201518)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent

   

(R)-1-Boc-3-(Cbz-amino-methyl)-piperidine

(R)-1-Boc-3-(Cbz-amino-methyl)-piperidine

C19H28N2O4 (348.20489680000003)


   

(S)-2-(DIBENZYLAMINO)-5-(1H-PYRROL-1-YL)PENTAN-2-OL

(S)-2-(DIBENZYLAMINO)-5-(1H-PYRROL-1-YL)PENTAN-2-OL

C23H28N2O (348.2201518)


   

6-(tert-Butyloxycarbonyl-methylamino)-5-methylpyridine-3-boronic acid pinacol ester

6-(tert-Butyloxycarbonyl-methylamino)-5-methylpyridine-3-boronic acid pinacol ester

C18H29BN2O4 (348.2220264)


   

4-(carboxy-p-tolyl-methyl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester

4-(carboxy-p-tolyl-methyl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester

C19H28N2O4 (348.20489680000003)


   

Carpindolol

Carpindolol

C19H28N2O4 (348.20489680000003)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist

   

tert-Butyl 2-((3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)amino)acetate

tert-Butyl 2-((3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)amino)acetate

C18H29BN2O4 (348.2220264)


   

TERT-BUTYL 4-(((BENZYLOXY)CARBONYL)AMINO)-4-METHYLPIPERIDINE-1-CARBOXYLATE

TERT-BUTYL 4-(((BENZYLOXY)CARBONYL)AMINO)-4-METHYLPIPERIDINE-1-CARBOXYLATE

C19H28N2O4 (348.20489680000003)


   

1-Butyl-3-methylimidazolium dibutyl phosphate

1-Butyl-3-methylimidazolium dibutyl phosphate

C16H33N2O4P (348.2177828)


   

CARBAMIC ACID, [TRANS-4-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]CYCLOHEXYL]-, PHENYLMETHYL ESTER

CARBAMIC ACID, [TRANS-4-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]CYCLOHEXYL]-, PHENYLMETHYL ESTER

C19H28N2O4 (348.20489680000003)


   

Methyl 1-Benzyl-4-(Boc-amino)piperidine-4-carboxylate

Methyl 1-Benzyl-4-(Boc-amino)piperidine-4-carboxylate

C19H28N2O4 (348.20489680000003)


   

(3-METHYL-PIPERAZIN-1-YL)-PHENYL-METHANONE

(3-METHYL-PIPERAZIN-1-YL)-PHENYL-METHANONE

C19H28N2O4 (348.20489680000003)


   

(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ETHYL-AMINE

(4-BENZYL-MORPHOLIN-2-YLMETHYL)-ETHYL-AMINE

C19H28N2O4 (348.20489680000003)


   

benzyl 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]piperidine-1-carboxylate

benzyl 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]piperidine-1-carboxylate

C19H28N2O4 (348.20489680000003)


   

1-N-Cbz-4-Boc-(Aminomethyl)piperidine

1-N-Cbz-4-Boc-(Aminomethyl)piperidine

C19H28N2O4 (348.20489680000003)


   

P-CYANOBENZYLIDENE P-NONYLOXYANILINE

P-CYANOBENZYLIDENE P-NONYLOXYANILINE

C23H28N2O (348.2201518)


   

2-(4-Boc-piperazinyl)-4-phenylbutanoic acid

2-(4-Boc-piperazinyl)-4-phenylbutanoic acid

C19H28N2O4 (348.20489680000003)


   

1-Benzyl 4-(2-methyl-2-propanyl) (5R)-5-methyl-1,4-diazepane-1,4-dicarboxylate

1-Benzyl 4-(2-methyl-2-propanyl) (5R)-5-methyl-1,4-diazepane-1,4-dicarboxylate

C19H28N2O4 (348.20489680000003)


   

(6aS,10aR)-6,6,9-trimethyl-3-phenethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol

(6aS,10aR)-6,6,9-trimethyl-3-phenethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol

C24H28O2 (348.2089188)


   
   

Iferanserin

Iferanserin

C23H28N2O (348.2201518)


C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Iferanserin (S-MPEC) is a selective 5-HT receptor (serotonin receptor) antagonist with an affinity for 5-HT2A receptor. Iferanserin has the potential for internal hemorrhoid disease treatment[1].

   

(Z)-4-(2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid

(Z)-4-(2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid

C24H28O2 (348.2089188)


   

(3R,10R)-10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyundecanoic acid

(3R,10R)-10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyundecanoic acid

C17H32O7 (348.21479220000003)


   

(3R)-11-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyundecanoic acid

(3R)-11-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyundecanoic acid

C17H32O7 (348.21479220000003)


   

9alpha-Fluoro-11beta-hydroxy-4-pregnene-3,20-dione

9alpha-Fluoro-11beta-hydroxy-4-pregnene-3,20-dione

C21H29FO3 (348.2100616)


   

21-Fluoro-11-hydroxy-pregn-4-ene-3,20-dione, (11beta)-

21-Fluoro-11-hydroxy-pregn-4-ene-3,20-dione, (11beta)-

C21H29FO3 (348.2100616)


   

9-Fluoro-17beta-hydroxy-6alpha,17-dimethylandrost-4-ene-3,11-dione

9-Fluoro-17beta-hydroxy-6alpha,17-dimethylandrost-4-ene-3,11-dione

C21H29FO3 (348.2100616)


   

6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate

6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate

C21H29FO3 (348.2100616)


   

2-[(1S,3S,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

2-[(1S,3S,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

C19H28N2O4 (348.20489680000003)


   

2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

C19H28N2O4 (348.20489680000003)


   

2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

C19H28N2O4 (348.20489680000003)


   

2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide

C19H28N2O4 (348.20489680000003)


   

11beta-Hydroxy-9alpha-fluoroprogesterone

9alpha-Fluoro-11beta-hydroxy-4-pregnene-3,20-dione

C21H29FO3 (348.2100616)


   

6alpha-Fluorotestosterone acetate

6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate

C21H29FO3 (348.2100616)


   

bixin dialdehyde

bixin dialdehyde

C24H28O2 (348.2089188)


An apo carotenoid that is the dialdehyde obtained by reduction of the terminal methyl ester and carboxy groups of bixin.

   

Cyclopropylfentanyl

Cyclopropylfentanyl

C23H28N2O (348.2201518)


   
   

AC260584

AC260584

C20H29FN2O2 (348.22129459999996)


AC260584 is an M1 muscarinic receptor allosteric agonist with a pEC50 of 7.6.

   

BDP9066

BDP9066

C20H24N6 (348.20623439999997)


BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.

   

(1r,9r,12s,14r)-9,13,13-trimethyl-3-(2-phenylethyl)-8-oxatetracyclo[7.4.1.0²,⁷.0¹²,¹⁴]tetradeca-2,4,6-trien-5-ol

(1r,9r,12s,14r)-9,13,13-trimethyl-3-(2-phenylethyl)-8-oxatetracyclo[7.4.1.0²,⁷.0¹²,¹⁴]tetradeca-2,4,6-trien-5-ol

C24H28O2 (348.2089188)


   

2-(3,7-dimethylocta-2,6-dien-1-yl)-5-(2-phenylethenyl)benzene-1,3-diol

2-(3,7-dimethylocta-2,6-dien-1-yl)-5-(2-phenylethenyl)benzene-1,3-diol

C24H28O2 (348.2089188)


   

(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-{[(2s)-2-methylbutoxy]methyl}-2-(2-methylpropoxy)oxan-3-yl acetate

(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-{[(2s)-2-methylbutoxy]methyl}-2-(2-methylpropoxy)oxan-3-yl acetate

C17H32O7 (348.21479220000003)


   

4,5-dihydroxy-6-[(2-methylbutoxy)methyl]-2-(2-methylpropoxy)oxan-3-yl acetate

4,5-dihydroxy-6-[(2-methylbutoxy)methyl]-2-(2-methylpropoxy)oxan-3-yl acetate

C17H32O7 (348.21479220000003)


   

({5-hexyl-7-oxo-decahydropyrrolo[2,1-j]quinolin-3-yl}methyl)sulfanylcarbonitrile

({5-hexyl-7-oxo-decahydropyrrolo[2,1-j]quinolin-3-yl}methyl)sulfanylcarbonitrile

C20H32N2OS (348.2235222)


   

2-(3,7-dimethylocta-2,6-dien-1-yl)-5-[(1e)-2-phenylethenyl]benzene-1,3-diol

2-(3,7-dimethylocta-2,6-dien-1-yl)-5-[(1e)-2-phenylethenyl]benzene-1,3-diol

C24H28O2 (348.2089188)